Issued: 1 June 2018, London UK - LSE Announcement
GSK completes Consumer Healthcare buyout
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has completed the buyout of Novartis' 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion*).
The transaction, which was previously announced on 27 March 2018 and described in the circular published on 13 April 2018, was approved by shareholders on 3 May 2018.
GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.
*Sterling equivalent value calculated net of hedging contracts
GSK enquiries: |
|
|
|
UK Media enquiries: |
Simon Steel |
+44 (0) 20 8047 5502 |
(London) |
|
|
|
|
US Media enquiries: |
Sarah Spencer |
+1 215 751 3335 |
(Philadelphia) |
|
|
|
|
Analyst/Investor enquiries: |
Sarah Elton-Farr |
+44 (0) 20 8047 5194 |
(London) |
|
James Dodwell |
+44 (0) 20 8047 2406 |
(London) |
|
Danielle Smith |
+44 (0) 20 8047 7562 |
(London) |
|
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
|
|
|
|
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017. |
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
